Nature feature: “Equitable Drug Access: Small-Scale Manufacturing Units Can Help,” co-written by RSV Global Access Fellows Taylor Rose and Anthony Bogachev

Written By Amanda Waldhauser

https://www.nature.com/articles/d41586-022-02803-8

Roivant Social Ventures congratulates the authors (including RSV Global Access Fellows Taylor Rose and Anthony Bogachev) on their letter to the editor published this week in Nature! The letter focuses on how small-scale manufacturing units can help bolster equitable drug access.

The COVID-19 pandemic has underscored the importance of equitable distribution of vaccines and therapeutics for LMICs, and small-footprint manufacturing platforms that can be flexibly adapted to produce a wide variety of products and scaled to meet regional demand offer a compelling alternative to conventional pharmaceutical-manufacturing facilities.

We believe that this type of platform being developed by our partner Sunflower Therapeutics, to produce a variety of biologics such as hormones, cytokines, and vaccine components, will be a great step forward for global equitable access.

This letter to the editor was written by Rachel Chikwamba, Kerry Love, Anthony Bogachev, Ameer B., Taylor Rose, and Fil (Filippo) Randazzo. You can access the publication directly here: https://lnkd.in/gikk5ctb

Amanda Waldhauser
Previous

Los Angeles Times feature: “Why the lack of diversity in drug industry leadership is hurting women and people of color,” written by Lindsay Androski, RSV CEO
Next

Health Affairs feature: “How The Next NIH Director Can Ensure Global Equitable Access To Medical Technologies” by Andrew Spencer Goldman and Reshma Ramachandran